Determining whether Puma Biotechnology (PBYI) represents a strong purchase depends heavily on an investor's tolerance for small-cap oncology risk and clinical pipeline volatility. While the company maintains a commercialized product, Nerlynx, providing baseline revenues and positive earnings per share, biotech equities carry inherent binary trial risks and regulatory hurdles. Comprehensive individual portfolio due diligence is essential before committing capital.